FilingSEC EDGAR8-K
Fate Therapeutics Secures $15 Million CIRM Grant for FT819 Phase 2 Trial
· SEC accepted
StagePhase 2
Filing content
The company received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN clinical trial of FT819 for lupus nephritis.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…